Try our Advanced Search for more refined results

UCB, Inc. v. Accord Healthcare, Inc.

  1. August 24, 2018

    Full Fed. Circ. Won't Rethink Upholding UCB's Vimpat Patent

    The full Federal Circuit on Friday shot down a request by multiple generic-drug makers to reconsider a panel's split decision upholding the validity of a UCB Inc. patent covering the epilepsy drug Vimpat.

  2. July 20, 2018

    Full Fed. Circ. Should Nix UCB's Vimpat Patent, Accord Says

    Generic-drug makers Accord Healthcare Inc. and Intas Pharmaceuticals Ltd. on Thursday urged the full Federal Circuit to consider invalidating a UCB Inc. patent covering the epilepsy drug Vimpat, arguing that the court's panel relied on subjective criteria to uphold the patent instead of legally mandated objectivity.

  3. May 23, 2018

    UCB's Epilepsy Drug Patent Win Upheld By Fed. Circ.

    The Federal Circuit on Wednesday affirmed a Delaware federal court's finding that a UCB Inc. patent on the epilepsy drug Vimpat is not invalid for double patenting or obviousness, upholding the company's win over a slew of generics makers including Mylan and Accord.

  4. August 08, 2017

    Generic Giants Ask Fed. Circ. To Nix Vimpat Patent

    Actavis Inc., Mylan Pharmaceuticals Inc. and other drug companies teamed up Tuesday for an assault on UCB Inc.'s patent for the anti-convulsant Vimpat at the Federal Circuit, seeking the chance to market generic versions of the epilepsy treatment.